Cardiff’s New £1.6 Billion Cancer Centre Faces Financial Scrutiny

A recent report has highlighted the substantial financial implications of building and operating the new Velindre Cancer Centre in Cardiff, which is projected to cost approximately £1.6 billion over the next 25 years. Initially estimated at £562 million when the Welsh Government approved the business case in 2021, the cost has escalated significantly, primarily due to delays and inflation.

According to the report published by Audit Wales, the development contract for the Velindre Cancer Centre is expected to total £885 million over a quarter of a century. This figure includes £321 million in construction costs. Additionally, operating expenses, including bringing the centre into full operation and ongoing management, are projected to reach at least £765 million. The project has garnered considerable public attention, not only for its financial scale but also due to its impact on local green spaces.

Concerns regarding the construction of the cancer centre have been voiced by community members, especially regarding its effect on the Northern Meadows and Lady Cory Field. Protests have occurred since the project’s inception in 2018, with some demonstrators even facing arrest in 2021 during attempts to halt construction activities. These green spaces are valued by local residents and walkers, raising questions about the balance between health infrastructure and environmental preservation.

In March 2024, following approval from the Welsh Government, Velindre University NHS Trust entered into a long-term contract with the private consortium ACORN. This agreement involves the design, construction, financing, and maintenance of the new centre. The funding model employed is known as the ‘mutual investment model’ (MIM), which allows private sector investment to cover upfront costs in exchange for an annual fee from public funds. This financing method has been utilized in other significant infrastructure projects in Wales, such as the dualling of the Heads of the Valleys road.

Audit Wales has scrutinized the decision-making processes undertaken by the health trust and the Welsh Government, emphasizing the necessity of sound financial planning given the substantial long-term costs. The report concludes that the trust adhered to established business practices and received adequate scrutiny during the procurement process. While there are recommendations for improvement, the integrity of the final decisions to proceed with the project remains intact.

Adrian Crompton, the Auditor General for Wales, noted that while the decisions regarding the Velindre Cancer Centre were justified, the path ahead may not be without complications. He stated, “The processes followed by the Trust and the Welsh Government during the period we examined have, overall, provided a sound enough basis for those decisions.” He further cautioned that it would take time before a comprehensive assessment of the project’s value for money could be accurately determined.

In response to the findings, Velindre University NHS Trust expressed its satisfaction with the report. Interim Chief Executive Officer, Carl James, stated, “The findings of this Audit Wales report provide important independent assurance about the way in which decisions on the new Velindre Cancer Centre have been taken.” He emphasized the project’s potential to revolutionize cancer care in the region, stating that it aims to enhance diagnostic capabilities and increase access to innovative treatments.

The new Velindre Cancer Centre is slated to open in the spring of 2027, replacing the existing facility that has been operational for nearly 70 years. As the project progresses, stakeholders will closely monitor its financial implications and its capacity to deliver on the promised improvements in cancer care. The findings from Audit Wales will likely play a critical role in shaping public perception and ensuring accountability as this significant investment in health infrastructure unfolds.